Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients.

Extramedullary tumor Molecular biology Radiation therapy Recurrence Spinal tumor Spine

Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
May 2021
Historique:
received: 21 12 2020
accepted: 12 02 2021
pubmed: 25 2 2021
medline: 5 2 2022
entrez: 24 2 2021
Statut: ppublish

Résumé

Myxopapillary ependymoma (MPE) is the most frequent tumor affecting the medullary conus. The surgical therapeutic management is still debated and only few studies have focused on the postoperative clinical outcome of patients. This study aimed to demonstrate long-term postoperative outcome and to assess the predictive factors of recurrence as well as the clinical evolution of these patients. From 1984 to 2019, in four French centers, 101 adult patients diagnosed with MPE were retrospectively included. Median age at surgery was 39 years. Median tumor size was 50 mm and lesions were multifocal in 13% of patients. All patients benefited from surgery and one patient received postoperative radiotherapy. Gross total resection was obtained in 75% of cases. Sixteen percent of patients presented recurrence after a median follow-up of 70 months. Progression free survival at 5 and 10 years were respectively estimated at 83% and 79%. After multivariable analysis, sacral localization, and subtotal resection were shown to be independently associated with tumor recurrence. 85% of the patients had a favorable evolution concerning pain. 12% of the patients presented a postoperative deterioration of sphincter function and 4% of motor function. Surgery alone is an acceptable option for MPE patients. Patients with sacral location or incomplete resection are at high risk of recurrence and should be carefully monitored.

Identifiants

pubmed: 33624261
doi: 10.1007/s11060-021-03717-7
pii: 10.1007/s11060-021-03717-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

491-499

Références

Bates JE, Choi G, Milano MT (2016) Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. J Neurooncol 129:251–258. https://doi.org/10.1007/s11060-016-2167-0
doi: 10.1007/s11060-016-2167-0 pubmed: 27306443
Ellison DW, Aldape KD, Capper D et al (2020) cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. https://doi.org/10.1111/bpa.12866
doi: 10.1111/bpa.12866 pubmed: 33141488
Louis DN, Ohgaki H, Wiestler OD, et al (2016) Ependymal tumours. In: WHO Classification of Tumours of the Central Nervous System. 4th Edition Revised, the International Agency for Research on Cancer (IARC), pp 101–115
Abul-Kasim K, Thurnher MM, McKeever P, Sundgren PC (2008) Intradural spinal tumors: current classification and MRI features. Neuroradiology 50:301–314. https://doi.org/10.1007/s00234-007-0345-7
doi: 10.1007/s00234-007-0345-7 pubmed: 18084751
Pusat S, Erbaş YC, Göçmen S et al (2019) Natural course of myxopapillary ependymoma: unusual case report and review of literature. World Neurosurg 121:239–242. https://doi.org/10.1016/j.wneu.2018.10.028
doi: 10.1016/j.wneu.2018.10.028 pubmed: 30321682
Ngo TP, Dufton J, Stern PJ, Islam O (2013) Myxopapillary ependymoma as a cause of back pain in a young male—a case report. J Can Chiropr Assoc 57:150–155
pubmed: 23754860 pmcid: 3661182
Asazuma T, Toyama Y, Suzuki N et al (1999) Ependymomas of the spinal cord and cauda equina: an analysis of 26 cases and a review of the literature. Spinal Cord 37:753–759. https://doi.org/10.1038/sj.sc.3100902
doi: 10.1038/sj.sc.3100902 pubmed: 10578245
Sakai Y, Matsuyama Y, Katayama Y, et al (2009) Spinal myxopapillary ependymoma: neurological deterioration in patients treated with surgery. Spine (Phila Pa 1976) 34:1619–1624. https://doi.org/ https://doi.org/10.1097/BRS.0b013e3181a983d8
Feldman WB, Clark AJ, Safaee M et al (2013) Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. J Neurosurg Spine 19:471–476. https://doi.org/10.3171/2013.6.SPINE12927
doi: 10.3171/2013.6.SPINE12927 pubmed: 23971762
Weber DC, Wang Y, Miller R et al (2015) Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro Oncol 17:588–595. https://doi.org/10.1093/neuonc/nou293
doi: 10.1093/neuonc/nou293 pubmed: 25301811
Pica A, Miller R, Villà S et al (2009) The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys 74:1114–1120. https://doi.org/10.1016/j.ijrobp.2008.09.034
doi: 10.1016/j.ijrobp.2008.09.034 pubmed: 19250760
Pesce A, Palmieri M, Armocida D et al (2019) Spinal myxopapillary ependymoma: the Sapienza University experience and comprehensive literature review concerning the clinical course of 1602 patients. World Neurosurg 129:245–253. https://doi.org/10.1016/j.wneu.2019.05.206
doi: 10.1016/j.wneu.2019.05.206 pubmed: 31152881
Akyurek S, Chang EL, Yu T-K et al (2006) Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center J Neurooncol 80:177–183. https://doi.org/10.1007/s11060-006-9169-2
doi: 10.1007/s11060-006-9169-2 pubmed: 16648988
Abdulaziz M, Mallory GW, Bydon M et al (2015) Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. Neurosurg Focus 39:E8. https://doi.org/10.3171/2015.5.FOCUS15164
doi: 10.3171/2015.5.FOCUS15164 pubmed: 26235025
Tsai CJ, Wang Y, Allen PK, et al (2014) Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. Neurosurgery 75:205–214; discussion 213–214. https://doi.org/ https://doi.org/10.1227/NEU.0000000000000408
Bagley CA, Wilson S, Kothbauer KF, et al (2009) Long term outcomes following surgical resection of myxopapillary ependymomas. Neurosurg Rev 32:321–334; discussion 334. https://doi.org/ https://doi.org/10.1007/s10143-009-0190-8
Liu M, Jevtic S, Markham-Coultes K et al (2018) Investigating the efficacy of a combination Aβ-targeted treatment in a mouse model of Alzheimer’s disease. Brain Res 1678:138–145. https://doi.org/10.1016/j.brainres.2017.10.015
doi: 10.1016/j.brainres.2017.10.015 pubmed: 29066368
Kukreja S, Ambekar S, Sharma M et al (2015) Outcome predictors in the management of spinal myxopapillary ependymoma: an integrative survival analysis. World Neurosurg 83:852–859. https://doi.org/10.1016/j.wneu.2014.08.006
doi: 10.1016/j.wneu.2014.08.006 pubmed: 25108296
Wellik DM (2007) Hox patterning of the vertebrate axial skeleton. Dev Dyn 236:2454–2463. https://doi.org/10.1002/dvdy.21286
doi: 10.1002/dvdy.21286 pubmed: 17685480
Barton VN, Donson AM, Kleinschmidt-DeMasters BK et al (2010) Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol 20:560–570. https://doi.org/10.1111/j.1750-3639.2009.00333.x
doi: 10.1111/j.1750-3639.2009.00333.x pubmed: 19793339 pmcid: 2871180
Palm T, Figarella-Branger D, Chapon F et al (2009) Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer 115:3955–3968. https://doi.org/10.1002/cncr.24476
doi: 10.1002/cncr.24476 pubmed: 19536879
Gu S, Gu W, Shou J et al (2017) The molecular feature of HOX gene family in the intramedullary spinal tumors. Spine 42:291–297. https://doi.org/10.1097/BRS.0000000000000889
doi: 10.1097/BRS.0000000000000889 pubmed: 25785959
Lotan TL, Torres A, Zhang M et al (2017) Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. Oncotarget 8:22772–22782. https://doi.org/10.18632/oncotarget.15196
doi: 10.18632/oncotarget.15196 pubmed: 28186998 pmcid: 5410261
Amelot A, Peyre M, Mokhtari K, et al (2020) Primary Extraosseous Spinal Ewing’s Sarcomas (PESES): Should we be more aware about Diagnosis? Spine (Phila Pa 1976). https://doi.org/ https://doi.org/10.1097/BRS.0000000000003784

Auteurs

Anne-Sophie Montero (AS)

Department of Neurosurgery, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, 47-83, boulevard de L'Hôpital, 75651, Paris Cedex 13, France.

Suzanne Tran (S)

Department of Neuropathology, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, Paris, France.

Aymeric Amelot (A)

Department of Neurosurgery, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, 47-83, boulevard de L'Hôpital, 75651, Paris Cedex 13, France.

Félix Berriat (F)

Inserm U 1127, CNRS UMR 7225, UMR S 1127, Paris Brain Institute, ICM, Sorbonne Université, 75013, Paris, France.

Guillaume Lot (G)

Department of Neurosurgery, Fondation Ophtalmologique Rothschild, Paris, France.

Stephan Gaillard (S)

Department of Neurosurgery, Hôpital Foch, Suresnes, France.

Chiara Villa (C)

INSERM U 1016, Institut Cochin, 75014, Paris, France.
NCRS UMR 8104, 75014, Paris, France.
Université Paris Descartes-Université de Paris, 75006, Paris, France.
Department of Pathological Cytology and Anatomy, Foch Hospital, 92151, Suresnes, France.

Marc Polivka (M)

Department of Pathological Cytology and Anatomy, Lariboisière Hospital, APHP, 75010, Paris, France.

Clovis Adam (C)

Department of Neuropathology, GHU Paris-Sud-Hôpital Bicêtre, le Kremlin-Bicêtre, France.

Ahmed Idbaih (A)

Inserm, CNRS, UMR S 1127, Institut du Cerveau Et de La Moelle Épinière, ICM, Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, 75013, Paris, France.

Loïc Feuvret (L)

Department of Radiotherapy, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, Paris, France.

Alexandre Carpentier (A)

Department of Neurosurgery, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, 47-83, boulevard de L'Hôpital, 75651, Paris Cedex 13, France.

Fabrice Parker (F)

Department of Neurosurgery, Hôpitaux Universitaires Paris-Sud, AP-HP, Centre Hospitalier Universitaire Bicêtre, Paris, France.

Franck Bielle (F)

Department of Neuropathology, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, Paris, France.
Inserm U 1127, CNRS UMR 7225, UMR S 1127, Paris Brain Institute, ICM, Sorbonne Université, 75013, Paris, France.

Bertrand Mathon (B)

Department of Neurosurgery, Sorbonne University, AP-HP, La Pitié-Salpêtrière Hospital, 47-83, boulevard de L'Hôpital, 75651, Paris Cedex 13, France. bertrand.mathon@aphp.fr.
Inserm U 1127, CNRS UMR 7225, UMR S 1127, Paris Brain Institute, ICM, Sorbonne Université, 75013, Paris, France. bertrand.mathon@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH